Title
U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod
A Prospective Trial of U500 Regular Insulin by Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes and Severe Insulin Resistance Who Have Failed Previous Insulin Regimens
Phase
Phase 4Lead Sponsor
Mountain Diabetes and Endocrine CenterStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Type 2 Diabetes Insulin ResistanceIntervention/Treatment
insulin human ...Study Participants
21Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.
Patients with Type 2 diabetes who have severe insulin resistance and very large insulin requirements (over 1.4 units of insulin /kg/day) often fail insulin regimens with persistent poor blood glucose control when standard U-100 insulin formulations are used. This is due in part to poor absorption of the large insulin volumes required using these less concentrated standard insulin preparations. The hypothesis that using a concentrated form of insulin called U-500 Regular insulin and delivering it by infusion via insulin pump will lower the volume of insulin required and therefore improve insulin absorption, which will lead to improved blood glucose control, will be tested.
U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
Inclusion Criteria: Type 2 diabetes on stable insulin regimen with or without oral agents for at least 3 months HbA1c > 7% No significant cardiovascular, renal or other serious medical diseases Exclusion Criteria: HbA1c < 7% Chronic renal, hepatic, cardiovascular, or other serious medical illness Females of childbearing age not using adequate contraception Use of GLP mimetic
| Event Type | Organ System | Event Term | All Subjects Active |
|---|
HbA1c is expressed as a percentage. This measurement represents an average of plasma glucose concentration for about 3 months. We will report the change in HbA1c measured at 12 months vs Baseline.
For the purposed of this study, hypoglycemia is defined as a blood glucose measurement of less than 70 mg/dl. As part of of this study, subjects will wear a Continuous Glucose Monitor (CGM) for 72 hours to assess glycemic control. The percent of time in hypoglycemia is a part of the download from the CGM.
Overall satisfaction rated on a scale of 0-100 percent with higher numbers indicating greater satisfaction with the insulin delivery method.
